Cite
HARVARD Citation
Wagner-Johnston, N. et al. (2021). Outcomes of patients with up to 6 years of follow-up from a phase 2 study of idelalisib for relapsed indolent lymphomas. Leukemia & lymphoma. 62 (5), pp. 1077-1087. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Wagner-Johnston, N. et al. (2021). Outcomes of patients with up to 6 years of follow-up from a phase 2 study of idelalisib for relapsed indolent lymphomas. Leukemia & lymphoma. 62 (5), pp. 1077-1087. [Online].